OncoZenge Announces Read-out of Positive Stability Data for BupiZenge™

Stockholm, Sweden – April 4, 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innovative, non-opioid based treatment for oral pain, announces today that ongoing stability studies for the revised formulation of BupiZenge™ show positive results.

Stability studies of BupiZenge™ are ongoing in line with previous communication from the company. The data now obtained shows 3 months of positive results within the desired limits of the specification for the development of the latest formulation. This data complements earlier data and analyzes and confirms the flexibility that OncoZenge now possesses to take BupiZenge™ to the next clinical development phase and market approval, with different packaging options.

“We are pleased to confirm that we continue to receive positive stability data for the latest formulation of BupiZenge,” says Stian Kildal, CEO of OncoZenge. “This confirms the competence, methods, and experience that the team now possesses to create stable product formulations with bupivacaine in combination with different packaging options. In addition to our readiness to take BupiZenge™ into a Phase 3 program for Europe, these insights are also valuable for future opportunities to create product variants for other indications and dosage-levels, or for other future pipeline candidates with bupivacaine.”

BupiZenge™ – Potential to be the leading treatment for oral pain.

For additional information, please contact:
Stian Kildal, CEO, mobile: +46 76 115 3797, e-mail: [email protected]

Certified Adviser
OncoZenge’s Certified Adviser is Carnegie Investment Bank AB (publ).

OncoZenge AB
Gustavslundsvägen 34, 167 51 Stockholm, Sweden

About OncoZenge
OncoZenge develops a novel, effective, safe and well-tolerated treatment for oral pain in conditions where currently available treatment options either do not achieve sufficient pain relief or are associated with significant side effects. BupiZenge™ is a new oral lozenge formulation of bupivacaine, an anaesthetic with decades of clinical experience. OncoZenge's lead indication is oral pain due to an inflammatory condition called oral mucositis that affects millions of patients receiving cancer treatment. Oral mucositis causes profound physical and psychological suffering, and is a large unmet medical need for an effective, opioid-sparing treatment option. BupiZenge™ has shown significantly better pain relief compared to standard of care in this indication in a Phase 2 trial. OncoZenge is headquartered in Stockholm, Sweden, and its share is publicly traded on Nasdaq First North Growth Market under the ticker ONCOZ.